A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Evaluate the Efficacy in Reducing Atrial Fibrillation Burden (AFB) as Well as the Safety, Tolerability, and Pharmacokinetics of Oral PKN605 in Participants With Atrial Fibrillation
Latest Information Update: 05 Nov 2025
At a glance
- Drugs PKN 605 (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 05 Nov 2025 New trial record